Last reviewed · How we verify
Human Dopaminergic Progenitor Cells
Human Dopaminergic Progenitor Cells is a Cell therapy Biologic drug developed by iRegene Therapeutics Co., Ltd.. It is currently in Phase 2 development for Parkinson's disease. Also known as: NouvNeu001.
Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain.
Dopaminergic progenitor cells are thought to replace or repair dopamine-producing neurons in the brain. Used for Parkinson's disease.
At a glance
| Generic name | Human Dopaminergic Progenitor Cells |
|---|---|
| Also known as | NouvNeu001 |
| Sponsor | iRegene Therapeutics Co., Ltd. |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Human Dopaminergic Progenitor Cells are a type of cell therapy that aims to treat neurodegenerative disorders by replenishing dopamine-producing neurons.
Approved indications
- Parkinson's disease
Common side effects
Key clinical trials
- This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease. (PHASE1)
- A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease (PHASE3)
- An Exploratory Clinical Study of UX-DA001 in Subjects With Idiopathic Parkinson's Disease (PHASE1)
- Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease (PHASE1, PHASE2)
- A Phase I/III Clinical Study to Evaluate NouvNeu001 Injection for Multiple System Atrophy (PHASE1)
- A Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease (PHASE1)
- Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease (PHASE1)
- The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human Dopaminergic Progenitor Cells CI brief — competitive landscape report
- Human Dopaminergic Progenitor Cells updates RSS · CI watch RSS
- iRegene Therapeutics Co., Ltd. portfolio CI
Frequently asked questions about Human Dopaminergic Progenitor Cells
What is Human Dopaminergic Progenitor Cells?
How does Human Dopaminergic Progenitor Cells work?
What is Human Dopaminergic Progenitor Cells used for?
Who makes Human Dopaminergic Progenitor Cells?
Is Human Dopaminergic Progenitor Cells also known as anything else?
What drug class is Human Dopaminergic Progenitor Cells in?
What development phase is Human Dopaminergic Progenitor Cells in?
Related
- Drug class: All Cell therapy drugs
- Manufacturer: iRegene Therapeutics Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Parkinson's disease
- Also known as: NouvNeu001
- Compare: Human Dopaminergic Progenitor Cells vs similar drugs
- Pricing: Human Dopaminergic Progenitor Cells cost, discount & access